S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:SGEN

Seagen (SGEN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$228.74
$228.74
50-Day Range
$228.74
$228.74
52-Week Range
$123.77
$228.96
Volume
86 shs
Average Volume
1.48 million shs
Market Capitalization
$42.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$229.00

Seagen MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.1% Upside
$229.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-2.63
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.82) to ($1.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.24 out of 5 stars

Medical Sector

913th out of 939 stocks

Biotechnology Industry

34th out of 37 stocks

SGEN stock logo

About Seagen Stock (NASDAQ:SGEN)

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

SGEN Stock News Headlines

4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
MRNA Feb 2024 64.000 put
MRNA Feb 2024 77.000 call
The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
MRNA Feb 2024 67.000 put
SGEN Jan 2024 210.000 put
SGEN Jan 2024 235.000 put(CONTR
SGEN Dec 2023 195.000 put(CONTR
HBM Gets Health Boost From Drug Licensing Deals
What the Options Market Tells Us About Seagen
See More Headlines
Receive SGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Seagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGEN
CUSIP
81257810
Employees
3,256
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$229.00
High Stock Price Target
$229.00
Low Stock Price Target
$229.00
Potential Upside/Downside
+0.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-610,310,000.00
Pretax Margin
-32.12%

Debt

Sales & Book Value

Annual Sales
$2.30 billion
Book Value
$15.10 per share

Miscellaneous

Free Float
139,084,000
Market Cap
$42.93 billion
Optionable
Optionable
Beta
0.32

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Should I Buy Seagen Stock? SGEN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Seagen was last updated on Monday, March 25, 2024 at 11:05 PM.

Pros

Here are some ways that investors could benefit from investing in Seagen Inc.:

  • Seagen Inc. has a strong product portfolio including ADCETRIS, PADCEV, and TUKYSA, which are innovative therapies for cancer treatment.
  • Recent acquisition of Seagen Inc. shares by Hudson Bay Capital Management LP indicates investor confidence in the company's potential growth.
  • Seagen Inc. has collaboration agreements with reputable companies like Takeda Pharmaceutical, Merck, and Genmab, enhancing its research and development capabilities.
  • Seagen Inc. is continuously developing new therapies like TIVDAK, Ladiratuzumab Vedotin, and Disitamab Vedotin, expanding its product pipeline.
  • Despite being a subsidiary of Pfizer Inc., Seagen Inc. operates independently, allowing it to focus on its core competencies in biotechnology.

Cons

Investors should be bearish about investing in Seagen Inc. for these reasons:

  • Market volatility in the biotechnology sector can impact Seagen Inc.'s stock price, leading to potential investment risks.
  • Regulatory challenges and approval processes for new drugs can cause delays in product launches, affecting revenue generation.
  • Competition in the biotechnology industry is intense, with other companies also developing innovative cancer therapies, posing a threat to Seagen Inc.'s market share.
  • Fluctuations in healthcare policies and reimbursement rates can influence the adoption of Seagen Inc.'s products, affecting financial performance.
  • Investing in biotechnology companies like Seagen Inc. requires a high tolerance for risk due to the inherent uncertainties in drug development and commercialization.

SGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Seagen stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SGEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGEN, but not buy additional shares or sell existing shares.
View SGEN analyst ratings
or view top-rated stocks.

What is Seagen's stock price target for 2024?

2 brokerages have issued twelve-month price targets for Seagen's shares. Their SGEN share price targets range from $229.00 to $229.00. On average, they expect the company's share price to reach $229.00 in the next twelve months. This suggests a possible upside of 0.1% from the stock's current price.
View analysts price targets for SGEN
or view top-rated stocks among Wall Street analysts.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) posted its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by $0.33. The biotechnology company earned $648.65 million during the quarter, compared to analysts' expectations of $635.10 million. Seagen had a negative net margin of 32.61% and a negative trailing twelve-month return on equity of 28.06%. The company's revenue was up 27.1% compared to the same quarter last year. During the same period last year, the firm earned ($1.03) EPS.

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen Chief Executive Officer Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among the company's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Salesforce (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Who are Seagen's major shareholders?

Seagen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Clear Street Markets LLC (0.00%), Public Sector Pension Investment Board (0.00%), Mint Tower Capital Management B.V. (0.00%), Neuberger Berman Group LLC (0.00%), Cowen AND Company LLC (0.00%) and Segantii Capital Management Ltd (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David R Epstein, David W Gryska, Jean I Liu, Jean I Liu, Morgan E Obrien, Roger D Dansey, Roger D Dansey, Todd E Simpson, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends
.

Does Seagen have any subsidiaries?
The following companies are subsidiares of Seagen: Cascadian Therapeutics.
Read More
This page (NASDAQ:SGEN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners